




# ANNUAL REPORT 2021

THE POWER  
OF PRECISION.  
FOR EVERY  
ONCOLOGIST.  
TODAY.

2curex

# 2CUREX EQUITY STORY



# TABLE OF CONTENTS

|                                           |    |
|-------------------------------------------|----|
| 2cureX Equity Story . . . . .             | 2  |
| CEO Letter . . . . .                      | 4  |
| Financial Highlights for 2021 . . . . .   | 6  |
| Highlights in 2021 . . . . .              | 7  |
| Individualized Cancer Treatment . . . . . | 8  |
| Geographic Expansion . . . . .            | 11 |
| Multiple IndiTreat® tests . . . . .       | 13 |
| Corporate Governance . . . . .            | 16 |
| Management . . . . .                      | 19 |
| Clinical Advisory Board . . . . .         | 22 |
| Management Report . . . . .               | 23 |
| Significant Events . . . . .              | 24 |
| Result and Financial Position . . . . .   | 25 |
| Financial Overview . . . . .              | 27 |
| Additional Disclosures . . . . .          | 35 |
| Statement by Board of Directors . . . . . | 43 |
| Auditor's Report . . . . .                | 44 |

## CEO LETTER –

# A YEAR OF DEEP TRANSFORMATION

2021 was a year of deep transformation for 2cureX. After more than fourteen years at the helm, founder Ole Thastrup handed over the CEO role in February to the undersigned, an executive with extensive industry experience. This management transition was part of a larger overhaul to turn what had been a successful research-oriented organization into a fully fledged In Vitro Diagnostics player, a necessary step towards the vision of making Drug Sensitivity Testing part of routine clinical practice in oncology.

A redefinition of the product portfolio strategy, with the addition of two new products, the incorporation of several new management team members, the implementation of a new ISO 13485 certified Quality Management System, the dramatic expansion of our international footprint from six to fourteen countries or the complete renewal of the Clinical Advisory Board are just some of the goals we have achieved over the last twelve months.

After a very successful 2021, we can confidently say that we are ready for the next step. In 2022 we will continue to expand our geographic reach, making IndiTreat® present in at least 20 countries in Europe. We aim at having at least 30 hospitals routinely using IndiTreat® to design individual treatment plans for patients with cancer, and expect to generate a stable revenue flow that will mark the birth of a new segment in the IVD market.

## BUILDING ASSETS THAT ARE CRITICAL FOR SUCCESS

Over the years since its founding in 2006, 2cureX had created a solid asset base through its research and development activity: a proprietary technology platform – IndiTreat® –, an Artificial Intelligence image analysis system to assess the effect of drugs on the 3D-tumors – IndiNet –, a solid IP portfolio, and a network of strong scientific partnerships with leading hospitals and universities around Europe.

In 2021, we have focused our efforts on building additional assets that are critical for our success as an In Vitro Diagnostics (IVD) company: achieving ISO 13485 certification, establishing a large commercial distribution network throughout Europe and attracting highly experienced staff with strong IVD background.

On these pillars, 2cureX has expanded its lead in the race towards establishing a new category of products in the IVD space – Drug Sensitivity Testing – that will transform the way in which cancer patients are treated today and could become a market worth more than USD 1 billion.

## PRODUCT STRATEGY AND PORTFOLIO DEVELOPMENT

In the second quarter of the year, we announced a re-definition of our product portfolio strategy. Instead of having one product per cancer entity – e.g.: IndiTreat® colorectal, IndiTreat® ovarian or IndiTreat® pancreas –

we saw the opportunity to develop multiple tests for each of them, based on the different therapy decision-making points throughout the evolution of the patient journey: before surgery, after surgery, in late stages... The implication of this new approach is that the patient can be tested multiple times, with different IndiTreat® tests, instead of only once.

At the same time, we announced that we would focus our product development on colorectal cancer (CRC) initially. CRC presents approximately 500,000 new cases every year in Europe., and we have developed and launched three different IndiTreat® CRC tests: IndiTreat® mCRC Start, for first line treatment guidance, and IndiTreat® mCRC Explore and mCRC Extend, both aimed at guiding third line treatment. We estimate that approximately 250,000 patients in Europe initiate first line treatment every year, and some 90,000 patients go on third line therapy.

## GEOGRAPHIC ROLLOUT IN EUROPE

Each market in Europe is different and requires local approaches. Developing distribution network in Europe has therefore been one of our top priorities in 2021. Only with strong local sales and support infrastructures can we reach hundreds of hospitals, and thousands of oncologists and pathologists. Through our commercial partners, we are currently leveraging a team of more than 75 sales

specialists who are promoting IndiTreat® daily. In 2021, we signed four new distribution agreements with leading In Vitro Diagnostics companies: Werfen (Spain), Labormed (Slovenia), Omnigen (Turkey) and Diamedica (Latvia and Lithuania), quickly followed by two additional agreements in the first week of January with Perlan (Poland) and Promedica (Czech and Slovakia). These add to our previous agreements with Lab 52 (Portugal), NM Genomics (Bulgaria) and YourRad (Sweden, Norway, Finland). All in all, IndiTreat® is now being promoted in fourteen different countries, including Denmark (up from six countries back in August). The number of new colorectal cancer cases in these countries in 2020 exceeded 150,000.

Our goal in 2022 is to expand our presence to at least 20 countries in Europe.

#### READY FOR THE NEXT PHASE

Most cancer treatments today are prescribed based on generic guidelines, without any indication of the sensitivity of the patient's tumor to the various drugs that are available. This is far from optimal, as patients will receive treatments that won't benefit them – but will suffer their side effects anyway – while others who might respond won't get them. There's growing consensus that In Vitro drug sensitivity testing provides the required individual information, as reflected in the number

of articles, symposia, studies, and initiatives addressing the topic. Having a portfolio of tests already available, a commercial network promoting them to clinicians, and the clinical evidence to support our claims, we at 2cureX are in the best position to benefit from this wave. Convincing a significant number of hospitals to use our IndiTreat® tests at the end of 2022 will be the best proof that drug sensitivity testing has finally moved from being an interesting research tool to an essential diagnostic test, starting a new category that, over time, can benefit millions of patients every year. We are determined to lead this movement and make 2cureX a Global market leader, and hope for the continued support of our shareholders on our journey.

**Fernando Andreu, CEO**

May 3, 2022



*"We are determined to lead this movement and make 2cureX a Global market leader"*

**FERNANDO ANDREU, CEO**


# FINANCIAL HIGHLIGHTS FOR 2021

| (KSEK) if not stated otherwise                     | 2021<br>1/1-31/12 | 2020<br>1/1-31/12 |
|----------------------------------------------------|-------------------|-------------------|
| Net sales                                          | 0                 | 0                 |
| Profit before tax                                  | -22 479           | -8 591            |
| Earnings per share*                                | -1.15             | -0.54             |
| Equity ratio**                                     | 94%               | 93%               |
| Cash flow from operating activities                | -18 426           | -11 694           |
| Cash flow for the period                           | 14 092            | 25 513            |
| Cash and cash equivalents at the end of the period | 72 942            | 58 577            |
| Average number of shares                           | 16 418 767        | 13 604 775        |
| No. of shares by the end of the period             | 17 475 716        | 14 856 600        |

\*Earnings per share: Profit for the period divided by the average number of shares.

\*\*Equity ratio: Shareholder's equity divided by total capital.

# HIGHLIGHTS IN 2021





# INDIVIDUALIZED CANCER TREATMENT



"Seeing IndiTreat® products being rolled out and used at European hospitals is extremely comforting and demonstrates the huge progress we have made since our research-based approach fifteen years ago"

**Ole Thastrup**, CSO and Founder of 2cureX




# DRUG SENSITIVITY TESTING IS MAKING INDIVIDUALIZED CANCER TREATMENT A REALITY

Since the completion of the human genome in 2003, it was envisioned that identifying of genetic aberrations and associated identification of selective drugs would make personalized cancer treatment a reality. Now, almost 20 years later, it has not come to pass. Analyzing static features such as the expression expression of key drug targets or genomic analysis of therapeutically targetable cancer mutations has not, in a broad sense, made individualization of cancer treatment a reality.

The largest oncology society in Europe, ESMO (European Society for Medical Oncology) thus published results from 11 clinical trials in 2019, including more than 13 000 patients showing that only 0.8 – 3% of the cancer patients responded to drugs selected on the basis of genetic analysis.

Genetic analysis has actually identified a number of potentially attractive drug targets, and the pharma industry has successfully developed a large number of drugs against these targets. Still, it is only a small proportion of cancer patients that obtain clinical benefit from the static genetic approach. A possible explanation might be due to the fact that cellular signaling (Fig. 1) is very complex, highly dynamic, shows a tremendous redundancy and diversity between individual patients.

FIG 1: EXAMPLE OF CELLULAR SIGNALING IN CANCER



M. Panda & BK Biswal (2019): Cell signaling and cancer: a mechanistic insight into drug resistance.

Mol Biol Reports 46, 5645

**THE DYNAMIC MEASUREMENT OF DRUG SENSITIVITY PERFORMED BY THE INDITREAT® TESTS IS REIGNITING THE 20-YEAR-OLD HOPE OF INDIVIDUALIZING CANCER TREATMENT.**

At 2cureX we are “*humble spectators*” of this cellular complexity and have pioneered the development of a *dynamic* test: IndiTreat® that lets us study the dynamics of drug interactions/sensitivity in a patient’s cancer cells in real time. The dynamic testing is conducted in three dimensional micro-tumors that are true replicas of the individual patient’s tumor. We do not know in detail where the drug treatments interact; but we can show whether the tumor is sensitive to a specific treatment and identify the treatments to which the tumor is resistant.

2cureX’s first IndiTreat® products target different stages of metastatic colorectal cancer (mCRC). IndiTreat has, in the first prospective interventional clinical trial (TICC) in which a functional test is guiding cancer treatment, shown that IndiTreat-guidance can improve patient outcome by 150%.

The scientific and clinical environment is starting to recognize Drug Sensitivity testing as the “missing piece” in diagnostics that will allow individualized treatment of cancer patients. This realization has led the Dana-Farber Cancer Institute, Harvard Medical School (Boston, US) and the Fred Hutchinson Cancer Research Center (Seattle, US) to establish the Society for Functional Precision Medicine ([www.sfpm.io](http://www.sfpm.io)).

2cureX and its clinical partner Univ. Hospital Vejle, Denmark have been invited to present the IndiTreat test and the clinical results of the TICC trial at the Society for Functional Precision Medicine on the 2022.

Drug Sensitivity Testing is an all-new In Vitro Diagnostic concept. To establish a general clinical reach and acceptance, it is of tremendous value that highly prestigious international cancer institutions like Harvard Medical School and the Fred Hutchinson Cancer Center recognize the potential of dynamic functional testing.

**2CUREX FIRMLY BELIEVES THAT:**

**Drug Sensitivity Testing**

**Will Transform Oncology Practice**

**In The Same Way That Genomics Testing Did**

**Two Decades Ago**



## GEOGRAPHIC EXPANSION –

# DISTRIBUTORS, THE BASIS FOR SALES EXPANSION

One of the areas in which 2cureX has been particularly active in 2021 is developing our commercial network across Europe, which we decided to implement through distribution agreements with IVD companies in each country. We rapidly expanded from having a presence in six countries (Denmark, Sweden, Finland, Norway, Portugal and Bulgaria) to fourteen countries at the end of January 2022 (adding Spain, Latvia, Lithuania, Poland, Czech, Slovakia, Turkey and Slovenia). Our current distribution network reaches approximately 35% of the European population, 235 million people, with around 150,000 new colorectal cancer cases every year.

## MARKET ACCESS COMPLEXITY AND COUNTRY PRIORITIZATION

Each country in Europe has a different configuration in terms of their healthcare systems. Funding principles, the role of government in healthcare provision, organization, priorities, size, coverage... are different country to country, creating a very heterogeneous landscape that can only be addressed through deep local knowledge. For 2cureX, the best way to integrate this local knowledge is by finding local companies willing to become distributors of IndiTreat® in their territories.

This diversity in the market access steps and stakeholders leads to some countries being simpler in terms of introducing new medical technologies, while other countries are much more complex. Combining a score of market, access complexity with the size of the market we defined a prioritization matrix that has guided our search for distributors throughout the year, looking for the shortest path to sales. For some countries, we included the existence of a significant number of patients paying 'out of their own pocket' in our analysis.

## PROFILE OF OUR DISTRIBUTORS

The companies with which we engage are distributors of IVD products in their markets. They need to have oncology products in their portfolio, so that they are familiar with the challenges, stakeholders and processes associated with this specialty. Ideally, they are commercializing biomarker tests, and can promote the combination of those with our IndiTreat® drug sensitivity tests to provide the comprehensive picture the oncologist requires.

In our contractual agreements, the distributor takes over the responsibility of promoting IndiTreat® through their sales teams and in local events, signing sales contracts with the hospitals, managing the sample logistics

between the hospital and 2cureX facilities in Copenhagen, and the whole "Order-To-Collection" process with the hospital. 2cureX has the responsibility of training the distributor's sales teams, making joint customer visits with them, providing them with sales support materials – brochures, animations, presentations – and organizing international events such as conferences, webinars, etc.

The collaboration with our distributors is one of true partnership. There's a common understanding that introducing a new technology is a process that requires perseverance and long-term commitment, and it is with this spirit that we work together towards the vision of making drug sensitivity testing a routine procedure for every cancer patient.

## DISTRIBUTOR SETUP

The process between the signature of the contract and the distributor being fully operational can take several weeks. Some administrative steps need to be fulfilled, such as including the IndiTreat® products and services in the distributor's ERPs, quality and logistics systems. Sample collection sets need to be shipped from 2cureX to the distributor warehouses, and IndiTreat® training and promotional materials need to be translated into


local languages. Only when the distributor's sales and customer support teams are trained, including technical, medical and commercial strategy elements, are these teams prepared to explain the product to the oncologists and pathologists in their assigned hospitals.

### THE IGNITE PROGRAM

When introducing a radical innovation in healthcare, creating a critical mass of users as quickly as possible is critical. Finding the innovators that are willing to be first movers and allowing them to experience IndiTreat® in their real-life environments is therefore a crucial activity at this moment.

To facilitate this IndiTreat® experience and accelerate its adoption in clinical routine, 2cureX has launched the IGNITE program ("Inducing Growth through a Network of IndiTreat Evaluations"). Through this program, the hospitals get a limited number of patients who can be tested with IndiTreat® at no cost for them. In exchange, they are asked to share the results of their experience with 2cureX and with other hospitals, in public events or in one-to-one meetings.

In December 2021 we announced the first hospital that signed up to the IGNITE program (Fundación Jiménez Díaz, in Madrid). Shortly after that, in February, we disclosed that four hospitals were in the program already. IGNITE has been very well received by oncologists, and this has become a very valuable tool for our distributors, who, as another token of their long-term commitment to IndiTreat®, are funding part of the associated costs of the program.



# MULTIPLE INDITREAT® TESTS THROUGHOUT THE PATIENT JOURNEY

In Q2 2021, we announced a re-definition of our product portfolio strategy, based on the feedback we had obtained from potential customers. The new direction was based on two concepts: developing tests for specific treatment decision-making situations and focusing on gastrointestinal (GI) cancers, initially on colorectal cancer.

With this decision we better adapted our tests to the needs of the oncologist and the patient, while at the same time realizing synergies in product development and commercialization, ultimately expanding the potential market for IndiTreat®.

## ONE INDITREAT® TEST FOR EACH DECISION-MAKING POINT

Throughout the journey of a cancer patient, there are several moments at which a treatment decision must be made. In Stages II and III, patients might receive drug therapy prior or after surgery, while in Stage IV, they will get several lines of drug therapy as the tumor progresses. In each of these moments, the oncologist has to choose between different drugs and drug combinations, specific to that situation. We are developing a portfolio of IndiTreat® tests to support the therapy decision-making at each of these timepoints.

We include in each IndiTreat® test the tumor sensitivity profile for the specific drugs the oncologist needs to

choose from in that situation, giving them only information that is relevant and actionable for that decision. This makes it easier to integrate IndiTreat® in the existing clinical protocols of the hospital.

In practice, this means that patients can take several IndiTreat® tests throughout their journey, tailoring the treatment to their individual sensitivity profiles at each junction.

## FOCUSING ON GI CANCERS FOR DEVELOPMENT AND COMMERCIAL SYNERGIES

While the IndiTreat® technology can be applied to any solid tumors, different cancer entities –breast colorectal, pancreatic, ovarian...– behave differently, and require adjustments to the way tumoroids are cultured, how the images are interpreted by the Artificial Intelligence system, etc. Consequently, developing a new test within the same cancer entity requires less effort compared to a test in a different cancer entity.

We decided to focus our efforts initially on colorectal cancer (CRC). This is the second most common cause of cancer death in both men and woman. Approximately 500,000 people are diagnosed with colorectal cancer every year in Europe and almost 250,000 die every year for this cause. Considering the patient journey in colorectal cancer, we estimate at least six different

IndiTreat® tests could be developed to cover specific treatment decisions.

Cancer treatment is becoming more and more specialized. In most hospitals in Europe, oncologists are concentrating in one or another cancer entity, and we find specialists in breast cancer, specialists in gastrointestinal (GI) cancers or in gynecological cancers, for example. With our initial set of IndiTreat® tests we are targeting the GI oncologists.

To maximize our development and commercial synergies, we have defined our roadmap in stages, first developing the full portfolio of CRC tests, then moving to other cancer entities within the space of GI cancers (offering additional products to the same customer segment) and finally transitioning to other cancer entities when we have consolidated our position in GI.

## THREE TESTS AVAILABLE FOR METASTATIC COLORECTAL CANCER

2cureX's IndiTreat® portfolio is made of three tests (IndiTreat® mCRC Start, IndiTreat® mCRC Extend and IndiTreat® mCRC Explore) covering several treatment steps in metastatic colorectal cancer.

IndiTreat® mCRC Start provides information on patient sensitivity to drugs that are used in first line systemic



therapy. Getting the right therapy in first line is very important, because the treatment options in second and third line are conditioned by the drugs used in first line.

IndiTreat® mCRC Extend covers the treatments available to patients facing their third line, according to international guidelines. The information about individual sensitivity is very relevant for the oncologist and the patient because the drugs have significant toxicity, and they should only be used in patients with a reasonable expectation of benefiting from them.

IndiTreat® mCRC Explore also covers third line therapy but looking at drugs that can be used "off label", that is, they have been approved for indications other than metastatic colorectal (mCRC) cancer but have proven in clinical studies that some mCRC patients can also benefit from them. The value of this test is to identify those patients and expand their options if their healthcare system allows for the "off label" use of drugs.

Around 250,000 patients start first line treatment every year in Europe, meaning they could benefit from guidance with IndiTreat® mCRC Start. Some 90,000 patients every year see their disease progress after having received two lines of treatment. These are the patients that, while considering their third line treatment options, could benefit from IndiTreat® mCRC Extend or IndiTreat® mCRC Explore guidance.

### FUTURE PORTFOLIO EXPANSION

In 2021 we launched two tests (Extend and Start), and a third one has been added in 2022 (Explore). We plan to expand the IndiTreat® offering for CRC with one or

two additional tests, to be launched in 2023 – these tests require certification by a Notified Body according to the new IVD-R regulation, and the overall timeline for development, validation and certification is longer than it was under IVD-D –.

Our research in pancreatic cancer (entity within the group of GI cancers) is progressing as planned. In June 2021 we presented a poster at ESMO GI with the results showing the feasibility of the IndiTreat® technology on pancreatic cancer primary tumor. Additional data have been generated since then, and we expect the research project to be finished at the end of 2022, when the actual product development phase could start.







"Functional Tests improve the clinical benefit for cancer patients, especially in advanced stages, in an efficient and reliable way"

**Dr. Jesus Garcia-Foncillas**, *Director University Cancer Institute and the Department of Oncology at the University Hospital Fundación Jiménez Díaz in Spain*



# CORPORATE GOVERNANCE

The 2cureX group consists of a holding company, 2cureX AB (publ) (Sweden) that is listed at Nasdaq First North Growth Market, and two operational companies 2cureX A/S (Denmark) and 2cureX GmbH (Germany). 2cureX AB and 2cureX A/S have the same Board of Directors who has the overall responsibility of the governance structure for the 2cureX group.

Corporate governance is linked to compliance with Nasdaq First North Growth Market Rulebook and laws and regulations relevant for 2cureX.

Key aspects of the governance structure relate to shareholder's meetings, Article of Association, the composition of the Board of Director's and Board's annual wheel. The board of Directors has implemented relevant policies and procedures for 2cureX.





#### **POVL-ANDRÉ BENDZ**

*Chairman of 2cureX AB and 2cureX A/S*

Povl-André Bendz (B. 1962) is CEO of SeaHouse Capital and an Executive and Investor.

Povl-André has an M.Sc. from Copenhagen Business School and long experience from commercial and financial assignments within Medtech and Biotech. Povl-André has previously been CEO and owner at Upfront Chromatography, Executive Vice President and CFO at the Danish company Delta Technology for nine years and has long experience of board work.

Povl-André has been the chairman of 2cureX AB since 2017 and 2cureX A/S since 2014.

#### **2CUREX SHARES, OWNERSHIP AND WARRANTS**

104 458 shares; 80 000 warrants

#### **OTHER BOARD ASSIGNMENTS**

Audientes A/S (listed on Nasdaq First North Growth market Copenhagen), SeaHouse Capital ApS, Thornæs. Destilleri ApS, IMATRA Holding S.A., Agilco ApS

#### **INDEPENDENCE**

Independent of management, the company and major shareholders.



#### **JØRGEN DREJER**

*Board Member of 2cureX AB and 2cureX A/S*

Jørgen Drejer (B. 1955) is the founder and Chief Scientific Officer of Saniona AB.

Jørgen is an experienced entrepreneur and has previously founded a large number of biotech companies including NsGene and Sophion Biosciences. Jørgen is a member of the Danish Academy of Engineering Sciences and has also been a director of the Danish Research Council for Independent Research. Jørgen holds a doctorate in neurobiology from Copenhagen University and is the author of more than 75 scientific articles.

Jørgen has been a board member of 2cureX AB since 2017 and 2cureX A/S since 2017.

#### **2CUREX SHARES, OWNERSHIP AND WARRANTS**

14 102 shares; 40 000 warrants

#### **OTHER BOARD ASSIGNMENTS**

Saniona AB

#### **INDEPENDENCE**

Independent of management, the company and major shareholders.



#### **OLE THASTRUP**

*Board member and CSO of 2cureX AB and 2cureX A/S*

Ole Thastrup (B. 1953) is co-founder. He has been a board member of 2cureX since 2006.

Ole holds an MSc in Pharmacy and a PhD in Pharmacology and Medicinal Chemistry. Ole is also Professor at the University of Copenhagen. Prior to 2cureX Ole was Head of Carlsberg Biosector where he was responsible for Carlsberg's biomedical research. Before that, Ole was the scientific founder and Chief Scientific Officer of Biolumage A/S (now Thermo Fischer Biolumage) that was spun out of Novo Nordisk A/S. Ole is inventor of several families of globally issued patents. He has advised several venture funds and is member of granting institutions (e.g. Novo Nordisk Foundation).

#### **2CUREX SHARES, OWNERSHIP AND WARRANTS**

4 156 134 shares via own company

#### **OTHER BOARD ASSIGNMENTS**

OT311 ApS

#### **INDEPENDENCE**

Affiliated to management, the company and major shareholders



### **CAMILLA HUSE BONDESSON**

*Board Member of 2cureX AB and 2cureX A/S*

Camilla Huse Bondesson (B. 1958) is Executive and board member in Medtech companies.

Camilla has an Executive MBA from Stockholm University. Currently, she is Chairman of the Board of Gradientech AB, Immuneed AB and TdB Labs AB. Camilla has over thirty years of international operational and strategic experience from senior positions at companies in the biotechnology field, including as General Manager of Behring Diagnostica AB, International Product Manager for Biacore, Marketing Director of Amersham Biosciences (current GE Healthcare Life Sciences) and VP Marketing for Gyros AB. Since 2004 Camilla is working as a consultant and partner at Conlega, a consulting company focusing on Life Science.

Camilla has been a board member of 2cureX AB since 2019 and 2cureX A/S since 2019.

### **2CUREX SHARES, OWNERSHIP AND WARRANTS**

33 472 shares; 40 000 warrants

### **OTHER BOARD ASSIGNMENTS**

Immuneed AB; TdB Consultancy AB

### **INDEPENDENCE**

Independent of management, the company and major shareholders.



### **NILS BRÜNNER**

*Board member of 2cureXAB and 2cureX A/S*

Nils Brünner (B. 1952) is co-founder Scandion Oncology A/S.

Nils is a medical oncologist with extensive experience as both a clinician and as a biotech entrepreneur. Nils is a highly recognized scientist with more than 370 scientific papers especially in the field of translational cancer research. Nils is one of the founders of Scandion Oncology A/S

### **2CUREX SHARES, OWNERSHIP AND WARRANTS**

2 000 shares; 40 000 warrants

### **OTHER BOARD ASSIGNMENTS**

Gibson Oncology, GeneTelligence

### **INDEPENDENCE**

Independent of management, the company and major shareholders.



### **MICHAEL LUTZ**

*Board member of 2cureX AB and 2cureX A/S*

Michael Lutz (B. 1968) is CEO of HepaRegeniX GmbH (Tübingen, Germany)

Michael holds a PhD in Bio-organic Chemistry from Swiss Federal Institute of Technology at Zürich.

Michael Lutz is an experienced biotech entrepreneur who has spent the last 15 years at executive management positions with several US and European Life Sciences companies which he successfully established or built-up to a successful exit. Michael is CEO of HepaRegeniX GmbH (Tübingen, Germany).

Michael has been a board member of 2cureX A/S since 2020 and 2cureX AB since 2020.

### **2CUREX SHARES, OWNERSHIP AND WARRANTS**

10 000 shares; 40 000 warrants

### **OTHER BOARD ASSIGNMENTS**

HepaRegeniX GmbH  
Noscendo GmbH

### **INDEPENDENCE**

Independent of management, the company and major shareholders

# MANAGEMENT



## FERNANDO ANDREU

CEO

Fernando Andreu (B. 1964) is CEO of 2cureX AB and 2cureX A/S since 2021.

Fernando brings to the company more than 30 years' experience in the In Vitro Diagnostics industry, having held top management positions at companies like Chiron, Roche Diagnostics and Sysmex, always with a focus in Global Business Development. Most recent positions include CEO at Sysmex Inostics (affiliate of Sysmex developing Liquid Biopsy technologies and products in oncology), Senior Executive Officer at Sysmex EMEA, COO of Indivumed Group (multi-omics database and AI platform for cancer discovery) and CEO of Indivumed Inc (US affiliate of Indivumed).

He holds a Degree in Business Administration and an MBA from ESADE Business School (Barcelona) where he has also been a Professor, associated to the Business Strategy Department.

## 2CUREX SHARES, OWNERSHIP AND WARRANTS

7 987 shares; 700 000 warrants



## KENNETH G. JOHANSEN

Chief Financial Officer

Kenneth G. Johansen (B. 1976) joined 2cureX in 2021 as CFO.

With more than 15 years of experience in business development and financial administration from the intersection of the biomedical area and advanced data analysis, Kenneth is fully engaged in delivering excellent business operations. More recent and relevant experience includes COO of JADBIO (Greece), CEO of Raven biosciences (DK), CEO of QIAGEN Aarhus (DK) and CFO of CLC bio (DK).

In addition, he has several years of working in audit with KPMG (DK), and holds a BA in Financial Management and Accounting.

## 2CUREX SHARES, OWNERSHIP AND WARRANTS

0 shares



## OLE THASTRUP

CSO and Deputy CEO

Ole Thastrup (B. 1953) is co-founder. He has been a board member of 2cureX since 2006.

Reference is made to description on page 17.

## 2CUREX SHARES, OWNERSHIP AND WARRANTS

4 156 134 shares via own company

## OTHER BOARD ASSIGNMENTS

OT311 ApS

## INDEPENDENCE

Affiliated to management, the company and major shareholders

**HENRIK HARLING***Chief Medical Officer*

Henrik Harling (B. 1953) joined 2cureX in 2019 as CMO.

Henrik is experienced surgeon and researcher within colorectal cancer and Head of Digestive Disease Center at Bispebjerg University Hospital 2000-2016. He is one of the founders of the Danish Colorectal Cancer Group (DCCG) and Chairman of the Danish Colorectal Cancer Register from 1994 to 2010. DCCG is setting guidelines for colorectal cancer treatment and involved in deciding on implementation of new diagnostic technologies in Denmark.

**2CUREX SHARES, OWNERSHIP  
AND WARRANTS**

23 023 shares

**GRITH HAGEL***Head of Project Management*

Grith Hagel (B. 1959) is co-founder of 2cureX in 2006.

Grith has a comprehensive experience in developing and running drug screening campaigns. Grith is the inventor of several patents on advanced cell-based, high throughput screening technologies.

Grith Hagel was co-founder of BioImage A/S that was spun-out of Novo Nordisk. She was responsible for the development of functional cell-based assays, and for their transfer to partners like Amersham plc (now GE Healthcare).

**2CUREX SHARES, OWNERSHIP  
AND WARRANTS**

681 708 shares

**JÜRGEN KUPPER***Managing Director (2cureX GmbH)*

Jürgen Kupper (B. 1965) joined 2cureX in 2015.

He began his career at Evotec AG in 1999. Jürgen's previous experience include COO of Evotec Technologies, Product Leader for Live Cell Imaging at PerkinElmer and managing director of the diagnostic center at the University Medical Center Hamburg-Eppendorf (UKE). Jürgen holds a Ph.D. in Biophysics from Brandeis University, USA.

**2CUREX SHARES, OWNERSHIP  
AND WARRANTS**

123 400 shares




**JESPER FLOYD KRISTIANSEN**

*VP Business Development Europe*

Jesper Floyd Kristiansen (B. 1965) joined 2cureX in August 2021 as VP Business Development Europe.


Jesper has been working in the field of In Vitro Diagnostics since 2000. He established Dako (now Agilent) in Poland and ran their cancer diagnostics activities for 12 years. In addition to Poland, he was also involved in supporting the distributor business in East Europe and Africa. This was followed by two years in the infectious disease arena as VP Sales & Marketing at ArcDia International in Finland where he expanded the distributor network, among others. From 2014, Jesper was Export Director and responsible for setting up the global distributor network and developing the distributor sales in molecular diagnostic testing at Biocartis NV in Belgium.


**MARK GRAY**

*Director of Communications*

Mark Gray joined 2cureX in March 2022.

Originally a copywriter, Mark ran his own writing and branding agency for 15 years before joining Sysmex Europe, the global leader in haematology. At Sysmex, Mark was Assistant Director of Marketing Communications for seven years, where he was responsible for the company's brand presence and overall communications throughout the EMEA region.


**MANUEL FERNANDEZ**


*Director Quality & Regulatory*

Manuel Fernandez joined 2cureX in March 2022.

Manuel Fernández has nearly 30 years' experience in Diagnostics and Medical Devices. His academic background is in mechatronics, robotics and automation engineering, as well as biomedical engineering Bachelor's Degree. He also completed Masters Degree in Clinical Engineering and Radiation Physics.

Throughout his career he has led the QA / RA function in several companies, becoming an expert in all relevant ISO norms. He has deep knowledge of the regulatory landscapes in Europe, US, China and Asia Pacific, and has worked with Notified Bodies and competent regulatory authorities in major countries. He is a certified FDA-MDSAP Auditor, certified ISO 13485, ISO 27001 and ISO9001 Lead Auditor, certified FDA-Clinical Investigator Inspector and certified FDA Pharmaceutical QMS Auditor, among others.

## CLINICAL ADVISORY BOARD



**DR. JOHN L. MARSHALL**

Dr. John L. Marshall, MD is Chief, Hematology and Oncology at Georgetown University Hospital, and Professor of Medicine and Oncology at Georgetown University in Washington D.C.

He is Director at the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, Georgetown University and Director of Gastrointestinal Oncology at the Lombardi Comprehensive Cancer Center.

Dr. Marshall has authored more than 160 articles and is an internationally recognized expert in new drug development for GI cancer, with expertise in phases I-III trial design.

He has been the Principal Investigator for more than 100 clinical trials.



**DR. JESUS GARCIA-FONCILLAS**

Dr. Jesus Garcia-Foncillas, MD PhD is currently the Director of the University Cancer Institute and the Department of Oncology at the University Hospital "Fundacion Jimenez Diaz" in Spain.

He is also Professor of Oncology at the Autonomous University of Madrid (UAM), and Director of the Professorship on Molecular Individualized Medicine UAM-Merck.

He combines this with the roles of Director of the Translational Oncology Division at the Health Research Institute FJD-UAM and Chairman of the Comprehensive Cancer Program of four University Hospitals in Madrid. Prof. Garcia-Foncillas is author of more than 275 articles and several books on Cancer.



**DR. ANDREW BEGGS**

Dr. Andrew Beggs, is currently Professor of Cancer Genetics & Surgery at the Institute of Cancer and Genomic Sciences and Co-Lead of Molecular Oncology, Pathology and Genetics, University of Birmingham, UK.

He is also Head of West Midlands GI & Gynecology Cancer Tumour Board Cancer Research UK & RCSEng Advanced Clinician Scientist, Consultant Colorectal & General Surgeon.

Dr. Andrew Beggs is a recognized expert in individualizing cancer treatment by doing multidimensional diagnostic analysis including 3D micro-tumor analysis.

# MANAGEMENT REPORT

The Board of Directors and the Chief Executive Officer of 2cureX AB (publ), 559128-0077, hereby present the annual report of the parent company and the consolidated accounts for the financial year 2021-01-01 – 2021-12-31.

The result of the year's operations is shown by the following financial accounts, which shall be adopted by the Annual General Meeting.

## THE OPERATIONS IN GENERAL

2cureX has developed IndiTreat®, which is a family of IVD tests developed and run by 2cureX as an aid to predict cancer patient's response and resistance to different drug regimens. The tests assess the effect of exposing patient-derived 3D tumoroids in vitro to various drugs and drug combinations, and with the tests you can test cancer treatments on patient derived microtumors to:

- Predict tumor resistance and sensitivity to cancer drugs
- Select the most appropriate treatment, in accordance with guidelines or off-label
- Improve patient quality of life through in vitro testing of drug efficacy on the individual patient

Our IndiTreat® product family is patent-protected in major markets and has an CE-IVD mark. Our business model is based on a growing network of specialized

and professional Distributors, together with a direct ordering system with hospitals. Our test facilities are head quartered in Copenhagen, Denmark with further activities in our subsidiary in Hamburg, Germany. The parent company is seated in Malmö, Skåne county.

## GROUP

The Group includes the wholly owned Danish subsidiary 2cureX A/S. 2cureX A/S has a wholly owned German subsidiary operating as 2cureX GmbH. All operations are conducted through 2cureX A/S and 2cureX GmbH, and the only operational activities of 2cureX AB is to own the subsidiary 2cureX A/S. Apart from what is stated above, 2cureX AB does not have any participations in other companies.

## WARRANT PROGRAM FOR EMPLOYEES AND BOARD MEMBERS

The extra general meeting on November 5, 2020 resolved to establish a warrant program for three new board members. The warrant program totalling 120,000 warrants carry the right to subscribe for newly issued shares in 2cureX AB in the period from October 1, 2023 up to an including December, 31, 2023. Each subscription warrant entitles the holder to subscribe for 1 share, at a subscription price equal to 110 percent of the volume weighted average price at Nasdaq First North Growth Market during a period of ten trading days following the extra general meeting on November 5, 2020. Upon full exercise of the issued warrants, the share capital would increase by 12,000 SEK. The warrants will be subject to

the usual conversion terms in connection with new share issues etc.

The Annual General Meeting on May 27, 2021 resolved to establish a Series 2021/24 warrant program for the Group's CEO. The warrants, totalling 700 000 warrants, carry the right to subscribe for newly issued shares in 2cureX AB in the period April 1, 2022 to 30 June 2022 (233 333 warrants), in the period April 1, 2023 to June 30, 2023 233 333 warrants) and in the period April 1, 2024 to June 30, 2024 (233 334 warrants), respectively.

The Group's result for 2021 has been impacted by costs in the amount of 1 986 KSEK (399 KSEK) in the form of personnel costs.

## RESEARCH AND DEVELOPMENT

The Group will continue to invest in research and development activities related to the IndiTreat® product family, which includes further major cancers areas, AI development and product enhancements.

## EXPECTED FUTURE DEVELOPMENT

Considering the Group's robust financial position, the ability to continue as a going concern is deemed to be beyond doubt.

# SIGNIFICANT EVENTS DURING THE FINANCIAL YEAR

## Q1

- 2cureX appoints Fernando Andreu, an international Biotech executive, as new CEO
- The last patient was treated in 2cureX's interventional clinical trial (TICC) in metastatic colorectal cancer
- 2cureX appoints Kenneth Graabek Johansen, an experienced business and financial executive, as new CFO
- IndiTreat® selected for prestigious multinational ovarian cancer project (DECIDER)
- The clinical TICC trial met its primary endpoint

## Q2

- The exercise price for warrants of series TO1 determined as SEK 13.22
- Board and management of 2cureX exercise all held warrants of series TO1 for SEK 6.04 million
- 2cureX's CEO Fernando Andreu buys shares in the company
- Mangold Fondkommission AB published an Analyst Report on 2cureX

- Warrants of series TO1 were subscribed to approximately 96.75 percent and 2cureX AB receives approximately SEK 31.40 million
- 2cureX appoints 2 new VPs to accelerate the commercial efforts

## Q3

- 2cureX receives its ISO 13485:2016 certification, an important milestone in the company's efforts towards bringing 3D-microtumors to routine clinical practice
- 2cureX appoints Dr. John L. Marshall and Dr. Jesús García-Foncillas as new Clinical Advisors, both internationally highly recognized oncologists
- 2cureX announces in press release, that it is now able to predict response to anti-angiogenic drugs with a modified version of its IndiTreat® technology
- Specialized diagnostic solutions leader Werfen, to distribute 2cureX products in Spain

## Q4

- MicroCaT article published by EU

- New member of the Clinical Advisory Board, Professor Andrew Beggs
- 2cureX signs distribution agreement with Labormed in Slovenia
- 2cureX provides a Live Strategy Update regarding the company's product portfolio and commercialization strategy on the October 12, 2021
- 2cureX provides commercial goals for 2022 at Live Strategy Update on the October 12, 2021
- 2cureX successfully completes the EU project MicroCaT and receives the final financial tranche of a 3.0 MEUR grant
- Mangold Fondkommission AB publishes an updated Analyst Report on 2cureX
- First IndiTreat® order received from Labormed in Slovenia
- First hospital joins the IndiTreat® Evaluation Program IGNITE
- 2cureX launches IndiTreat® mCRC Start test to guide 1st line treatment
- 2cureX reaches the goals of the 2021 rollout plan
- New Distributor for IndiTreat® in Turkey through Omnigen Medical Products

FOR DETAILS OF HIGHLIGHT FOR 2021 SEE ABOVE AND BEGINNING OF 2022 WE HAVE HAD FOLLOWING MAJOR EVENTS:



# RESULT AND FINANCIAL POSITION

Net sales in 2021 amounted to 0 KSEK (0 KSEK). The Company had no sales during 2021; all income is attributable to various contributions and public grants.

The result for 2021 totaled -18 937 KSEK (-7 320 KSEK). The result for the period has been impacted by the conduct of clinical trials initiated to validate the IndiTreat® technology. A significant part of the clinical operations is funded by an EU grant named MicroCaT, recognized as Other operating income in the income statement.

The Group's cash and cash equivalents amounted to 72 942 KSEK (58 577 KSEK) as of 31 December 2021. Cash flow in 2021 amounted to 14 092 KSEK (25 513 KSEK). Cash flow from operating activities in 2021 amounted to -18 426 KSEK (-11 694 KSEK). The monthly burn rate is approximately 3.2 MSEK, which is in line with the expectations.

The Group's solidity as of 31 December 2021 amounted to 94 percent (93).

## Multi-annual overview (KSEK), Group

|                                            | 2021    | 2020   | 2019   | 2018   | 2017   |
|--------------------------------------------|---------|--------|--------|--------|--------|
| Net sales                                  | 0       | 0      | 0      | 0      | 47     |
| Earnings/loss after financial items        | -22 479 | -8 591 | -9 411 | -8 542 | -3 995 |
| Total assets                               | 79 160  | 63 044 | 37 841 | 24 026 | 22 846 |
| Equity ratio (%)                           | 94      | 93     | 74     | 57     | 89     |
| Average number of employees                | 14      | 13     | 11     | 9      | 8      |
| Basic and diluted earnings per share (SEK) | -1.15   | -0.54  | -0.68  | -0.70  | -0.37  |

## Multi-annual overview (KSEK), Parent Company

|                              | 2021   | 2020   | 2019   | 2018    | 2017<br>(3 mth) |
|------------------------------|--------|--------|--------|---------|-----------------|
| Net sales                    | 0      | 0      | 0      | 0       | 47              |
| Result after financial items | -3 809 | -2 028 | -1 917 | -11 446 | -1 024          |
| Balance sheet total          | 97 003 | 66 584 | 30 208 | 19 878  | 22 165          |
| Solidity (%)                 | 99.6   | 99.0   | 99.0   | 48.6    | 92.9            |
| Average number of employees  | 0      | 0      | 0      | 0       | 0               |

**SHARES**

There is one class of shares in 2cureX AB (publ). The Company's share is listed on Nasdaq First North Growth Market under the ticker "2CUREX". As of 31 December 2021, the number of shares amounted to 17 475 716 (14 856 660). The average number of shares during 2021 amounted to 16 418 767 (13 604 775).

| Shareholders                 | Number of shares  | Votes and capital (%) |
|------------------------------|-------------------|-----------------------|
| OT311 ApS                    | 4 156 134         | 23.8                  |
| Avanza Pension               | 1 898 243         | 10.9                  |
| Clear Stream Banking S.A.    | 938 492           | 5.4                   |
| SVM Verwal Tungsgesellschaft | 792 392           | 4.5                   |
| Grith Hagel                  | 681 708           | 3.9                   |
| Nordnet Pension              | 498 022           | 2.9                   |
| Sebastian M. Johannisson     | 354 800           | 2.0                   |
| Other shareholders           | 8 155 925         | 46.6                  |
|                              | <b>17 475 716</b> | <b>100.0</b>          |

| Development of the share capital | Year | Number of shares | Quota value | Total number of shares | Total share capital |
|----------------------------------|------|------------------|-------------|------------------------|---------------------|
| Company formation                | 2017 | 8 000 000        | 0.10        | 8 000 000              | 800 000             |
| New share issue                  | 2017 | 2 350 000        | 0.10        | 10 350 000             | 1 035 000           |
| New share issue                  | 2019 | 2 070 000        | 0.10        | 12 420 000             | 1 242 000           |
| New share issue                  | 2020 | 2 440 000        | 0.10        | 14 856 600             | 1 485 660           |
| New share issue                  | 2021 | 2 619 116        | 0.10        | 17 475 716             | 1 747 572           |

**RISK FACTORS**

The Board of Directors decides on the level of risk in the operations, and the decisions are made taking the CEO's proposals into account. The financial risks can primarily be divided into the following categories: market risks (including currency risks, interest rate risks and price risks), credit risks and liquidity risks. The risks that the Group faces are detailed below.

*Currency Risks*

The Group's revenue mostly comprises of received grants and contributions generated in local currency. This entails that the revenue is recognized in SEK, DKK and EUR. Acquisitions are also denominated in the local currency. The Group is thus not considered to be exposed to any significant currency risks aside from the translation in conjunction with the preparation of the consolidated accounts.

*Interest Rate Risks*

The Group's interest rate risks are restricted to bank deposits. The interest rate risk is considered to be in balance.

*Credit Risks*

The Group strives to have counterparties of the highest possible credit standards. The majority of the Group's sales can be carried out with a low level of credit risk.

*Liquidity Risks*

The Group is addressing its liquidity situation continuously. The Group's financial position is good, and the Board's assessment is that liquidity is sufficient to ensure continued operations. However, future financing needs may arise, and the Board therefore continuously evaluates possible financing opportunities. Liquidity is currently not considered to be a major risk area.

**APPROPRIATION OF PROFIT OR LOSS, (SEK)**

Proposed appropriations of the Parent Company's result

The following funds are available to the Annual General Meeting:

|                           |                   |
|---------------------------|-------------------|
| Other contributed capital | 111 864 370       |
| Retained earnings         | -13 165 683       |
| Result for the period     | -3 809 245        |
|                           | <b>94 889 442</b> |

The Board of Directors proposes the following distribution:

|                       |                   |
|-----------------------|-------------------|
| To be carried forward | 94 889 442        |
|                       | <b>94 889 442</b> |



# FINANCIAL OVERVIEW



# FINANCIAL OVERVIEW

## THE GROUP

### INCOME STATEMENT –THE GROUP

(KSEK)

Note

2021

1/1-31/12

2020

1/1-31/12

#### Operating income

|                               |   |              |               |
|-------------------------------|---|--------------|---------------|
| Net sales                     |   | 0            | 0             |
| Other operating income        | 3 | 7 391        | 15 391        |
| <b>Total operating income</b> |   | <b>7 391</b> | <b>15 391</b> |

#### Operating expenses

|                                       |   |                |                |
|---------------------------------------|---|----------------|----------------|
| Other external expenses               |   | -11 863        | -10 063        |
| Personnel costs                       | 4 | -17 976        | -12 360        |
| Depreciation of tangible fixed assets |   | -353           | -386           |
| <b>Total operating expenses</b>       |   | <b>-30 192</b> | <b>-22 809</b> |

#### Operating profit

**-22 801**      **-7 418**

#### Profit/loss from financial items

|                                                  |   |            |               |
|--------------------------------------------------|---|------------|---------------|
| Other financial income and other financial items | 6 | 322        | 0             |
| Financial expenses and other financial items     | 7 | 0          | -1 173        |
| <b>Total financial items</b>                     |   | <b>322</b> | <b>-1 173</b> |

#### Earnings/loss after financial items

**-22 479**      **-8 591**

|                              |   |       |       |
|------------------------------|---|-------|-------|
| Tax on earnings for the year | 8 | 3 542 | 1 271 |
|------------------------------|---|-------|-------|

#### Earnings/loss for the year

**-18 937**      **-7 320**

|                                        |  |            |            |
|----------------------------------------|--|------------|------------|
| Earnings per share (SEK)               |  | -1.15      | -0.54      |
| Average number of shares               |  | 16 418 767 | 13 604 775 |
| No. of shares at the end of the period |  | 17 475 716 | 14 856 600 |

**BALANCE SHEET – THE GROUP**

| (KSEK)                               | Note | 31/12-2021    | 31/12-2020    |
|--------------------------------------|------|---------------|---------------|
| <b>Assets</b>                        |      |               |               |
| <b>Fixed assets</b>                  |      |               |               |
| <b>Tangible fixed assets</b>         |      |               |               |
| Capitalized development expenditure  | 9    | 0             | 0             |
| Equipment, tools and fixtures        | 10   | 691           | 996           |
| <b>Total fixed assets</b>            |      | <b>691</b>    | <b>996</b>    |
| <b>Total fixed assets</b>            |      | <b>691</b>    | <b>996</b>    |
| <b>Current assets</b>                |      |               |               |
| Other receivables                    |      | 1 409         | 1 115         |
| Current tax receivable               |      | 3 571         | 1 219         |
| Prepaid expenses and deferred income | 16   | 547           | 1 137         |
| Cash and bank balances               | 17   | 72 942        | 58 577        |
| <b>Total current assets</b>          |      | <b>78 469</b> | <b>62 048</b> |
| <b>Total assets</b>                  |      | <b>79 160</b> | <b>63 044</b> |
| <b>Equity and liabilities</b>        |      |               |               |
| <b>Equity</b>                        | 12   |               |               |
| Share capital                        |      | 1 748         | 1 486         |
| Ongoing share issue                  |      | 1 068         | 0             |
| Other contributed capital            |      | 106 608       | 75 388        |
| Other equity                         |      | -16 143       | -10 690       |
| The result of the period             |      | -18 937       | -7 320        |
| <b>Total equity</b>                  |      | <b>74 344</b> | <b>58 864</b> |
| <b>Current liabilities</b>           |      |               |               |
| Accounts payable                     |      | 2 476         | 967           |
| Other liabilities                    |      | 896           | 1 050         |
| Accrued expenses and deferred income | 14   | 1 444         | 2 163         |
| <b>Total short-term liabilities</b>  |      | <b>4 816</b>  | <b>4 180</b>  |
| <b>Total equity and liabilities</b>  |      | <b>79 160</b> | <b>63 044</b> |

**CASH FLOW – THE GROUP**

| (KSEK)                                                                       | Note | 2021<br>1/1-31/12 | 2020<br>1/1-31/12 |
|------------------------------------------------------------------------------|------|-------------------|-------------------|
| <b>Operating activities</b>                                                  |      |                   |                   |
| Operating profit                                                             |      | -22 801           | -7 418            |
| Adjusted for non-cash flow items                                             | 15   | 1 928             | 684               |
| Interest net                                                                 |      | 322               | -240              |
| Tax received                                                                 |      | 1 228             | 1 507             |
| <b>Cash flow from operating activities before changes in working capital</b> |      | <b>-19 323</b>    | <b>-5 467</b>     |
| <b>Cash flow from changes in working capital</b>                             |      |                   |                   |
| Changes in operating receivables                                             |      | 328               | -676              |
| Change in operating liabilities                                              |      | 569               | -5 551            |
| <b>Cash flow from operating activities</b>                                   |      | <b>-18 426</b>    | <b>-11 694</b>    |
| <b>Investment activities</b>                                                 |      |                   |                   |
| Investment in tangible assets                                                |      | -32               | -403              |
| <b>Cash flow from investment activities</b>                                  |      | <b>-32</b>        | <b>-403</b>       |
| <b>Financing activities</b>                                                  |      |                   |                   |
| Rights issue                                                                 |      | 32 550            | 37 610            |
| <b>Cash flow from financing activities</b>                                   |      | <b>32 550</b>     | <b>37 610</b>     |
| <b>Cash flow for the year</b>                                                |      | <b>14 092</b>     | <b>25 513</b>     |
| Cash and cash equivalents at beginning of year                               |      | 58 577            | 33 720            |
| Exchange rate differences in cash and cash equivalents                       |      | 273               | -656              |
| <b>Cash and cash equivalents at end of year</b>                              | 17   | <b>72 942</b>     | <b>58 577</b>     |

## CHANGE OF EQUITY – THE GROUP

1/1-2020 – 31/12-2020

| (KSEK)                                           | Share capital | Other contributed capital | Other equity   | Result of the period | Total         |
|--------------------------------------------------|---------------|---------------------------|----------------|----------------------|---------------|
| <b>At the beginning of the period (1/1-2020)</b> | <b>1 242</b>  | <b>38 023</b>             | <b>-3 256</b>  | <b>-7 933</b>        | <b>28 076</b> |
| Outline of previous year's results               |               |                           | -7 933         | 7 933                | 0             |
| Issue of warrants                                |               |                           | 399            |                      | 399           |
| Currency exchange                                |               |                           | 100            |                      | 100           |
| Issue of shares                                  | 244           | 39 873                    |                |                      | 40 117        |
| Translation difference                           |               | -2 508                    |                |                      | -2 508        |
| The result of the period                         |               |                           |                | -7 320               | -7 302        |
| <b>At the end of the period (31/12-2020)</b>     | <b>1 486</b>  | <b>75 388</b>             | <b>-10 690</b> | <b>-7 320</b>        | <b>58 864</b> |

## CHANGE OF EQUITY – THE GROUP

1/1-2021 – 31/12-2021

| (KSEK)                                           | Share capital | Ongoing share issue | Other contributed capital | Other equity   | Result of the period | Total         |
|--------------------------------------------------|---------------|---------------------|---------------------------|----------------|----------------------|---------------|
| <b>At the beginning of the period (1/1-2021)</b> | <b>1 486</b>  | <b>0</b>            | <b>75 388</b>             | <b>-10 690</b> | <b>-7 320</b>        | <b>58 864</b> |
| Outline of previous year's results               |               |                     |                           | -7 320         | 7 320                | 0             |
| Rights issue                                     |               |                     |                           | 2 027          |                      | 2 027         |
| Issue costs                                      |               |                     | -1 968                    |                |                      | -1 968        |
| Issue of shares                                  | 262           |                     | 33 188                    |                |                      | 33 450        |
| Ongoing share issue                              |               | 1 068               |                           |                |                      | 1 068         |
| Translation difference                           |               |                     |                           | -160           |                      | -160          |
| The result of the period                         |               |                     |                           |                | -18 937              | -18 937       |
| <b>At the end of the period (31/12-2021)</b>     | <b>1 748</b>  | <b>1 068</b>        | <b>106 608</b>            | <b>-16 143</b> | <b>-18 937</b>       | <b>74 344</b> |

Pioneering products that improve the outcomes of cancer treatment.

# FINANCIAL OVERVIEW

## PARENT COMPANY

### INCOME STATEMENT – PARENT COMPANY

(KSEK)

Note

**2021**

1/1-31/12

**2020**

1/1-31/12

**Operating income**

Net sales

0

0

**Total operating income****0****0****Operating expenses**

Other external expenses

-1 898

-1 834

Personnel costs

4

-839

-659

**Total operating expenses****-2 737****-2 493****Operating profit****-2 737****-2 493****Profit/loss from financial items**

Earnings/loss from associated companies

5

-2 027

-399

Other financial income  
and other financial items

6

957

942

Financial expenses and other financial items

7

-2

-78

**Total financial items****-1 072****465****Profit before tax****-3 809****-2 028**

Tax on earnings for the year

8

0

0

**Earnings/loss for the year****-3 809****-2 028**

**BALANCE SHEET  
– PARENT COMPANY**

| (KSEK)                               | Note | 31/12-2021    | 31/12-2020    |
|--------------------------------------|------|---------------|---------------|
| <b>Assets</b>                        |      |               |               |
| <b>Fixed assets</b>                  |      |               |               |
| <b>Financial assets</b>              |      |               |               |
| Investment in subsidiaries           | 11   | 5 000         | 5 000         |
| Receivables from subsidiaries        | 13   | 24 275        | 23 318        |
| <b>Total financial assets</b>        |      | <b>29 275</b> | <b>28 318</b> |
| <b>Total fixed assets</b>            |      | <b>29 275</b> | <b>28 318</b> |
| <b>Current assets</b>                |      |               |               |
| Other receivables                    |      | 82            | 146           |
| Prepaid expenses and deferred income | 16   | 470           | 159           |
| Cash and bank balances               | 17   | 67 176        | 37 961        |
| <b>Total current assets</b>          |      | <b>67 728</b> | <b>38 266</b> |
| <b>Total assets</b>                  |      | <b>97 003</b> | <b>66 584</b> |

| (KSEK)                               | Note | 31/12-2021    | 31/12-2020    |
|--------------------------------------|------|---------------|---------------|
| <b>Equity and liabilities</b>        |      |               |               |
| <b>Equity</b>                        | 12   |               |               |
| <b>Restricted equity</b>             |      |               |               |
| Share capital                        |      | 1 748         | 1 486         |
| <b>Total restricted equity</b>       |      | <b>1 748</b>  | <b>1 486</b>  |
| <b>Non-restricted equity</b>         |      |               |               |
| Premium fund                         |      | 110 808       | 79 588        |
| Ongoing share issue                  |      | 1 068         | 0             |
| Balanced result                      |      | -13 165       | -13 164       |
| Earnings/loss for the year           |      | -3 809        | -2 028        |
| <b>Total non-restricted equity</b>   |      | <b>94 902</b> | <b>64 396</b> |
| <b>Total equity</b>                  |      | <b>96 650</b> | <b>65 882</b> |
| <b>Current liabilities</b>           |      |               |               |
| Accounts payable                     |      | 42            | 84            |
| Other liabilities                    |      | 1             | 82            |
| Accrued expenses and deferred income | 14   | 310           | 536           |
| <b>Total short-term liabilities</b>  |      | <b>353</b>    | <b>702</b>    |
| <b>Total equity and liabilities</b>  |      | <b>97 003</b> | <b>66 584</b> |



**CASH FLOW STATEMENT  
– PARENT COMPANY**

| (KSEK)                                                                           | Note | 2021<br>1/1-31/12 | 2020<br>1/1-31/12 |
|----------------------------------------------------------------------------------|------|-------------------|-------------------|
| <b>Operating activities</b>                                                      |      |                   |                   |
| Operating profit                                                                 |      | -2 737            | -2 493            |
| Interest paid                                                                    |      | -2                | -78               |
| <b>Cash flow from operating activities<br/>before changes in working capital</b> |      | <b>-2 739</b>     | <b>-2 571</b>     |
| <b>Cash flow from changes in working capital</b>                                 |      |                   |                   |
| Changes in operating receivables                                                 |      | -247              | -7                |
| Change in operating liabilities                                                  |      | -349              | 396               |
| <b>Cash flow from operating activities</b>                                       |      | <b>-3 335</b>     | <b>-2 182</b>     |
| <b>Financing activities</b>                                                      |      |                   |                   |
| Rights issue                                                                     |      | 32 550            | 37 610            |
| <b>Cash flow from financing activities</b>                                       |      | <b>32 550</b>     | <b>37 610</b>     |
| <b>Cash flow for the year</b>                                                    |      | <b>29 215</b>     | <b>35 427</b>     |
| Cash and cash equivalents<br>at beginning of year                                |      | 37 961            | 2 534             |
| <b>Cash and cash equivalents at end of year</b>                                  | 17   | <b>67 176</b>     | <b>37 961</b>     |

## CHANGE OF EQUITY – PARENT COMPANY

1/1-2020 – 31/12-2020

| (KSEK)                                           | Share capital | Other contributed capital | Other equity   | Result of the period | Total         |
|--------------------------------------------------|---------------|---------------------------|----------------|----------------------|---------------|
| <b>At the beginning of the period (1/1-2020)</b> | <b>1 242</b>  | <b>42 223</b>             | <b>-11 646</b> | <b>-1 917</b>        | <b>29 902</b> |
| Outline of previous year's results               |               |                           | -1 917         | 1 917                | 0             |
| Rights issue                                     | 244           | 39 873                    |                |                      | 40 117        |
| Issue costs                                      |               | -2 508                    |                |                      | -2 508        |
| Issue of warrants                                |               |                           | 399            |                      | 399           |
| The result of the period                         |               |                           |                | -2 028               | -2 028        |
| <b>At the end of the period (31/12-2020)</b>     | <b>1 486</b>  | <b>79 588</b>             | <b>-13 164</b> | <b>-2 028</b>        | <b>65 882</b> |

## CHANGE OF EQUITY – PARENT COMPANY

1/1-2021 – 31/12-2021

| (KSEK)                                           | Share capital | Ongoing share issue | Other contributed capital | Other equity   | Result of the period | Total         |
|--------------------------------------------------|---------------|---------------------|---------------------------|----------------|----------------------|---------------|
| <b>At the beginning of the period (1/1-2021)</b> | <b>1 486</b>  | <b>0</b>            | <b>79 588</b>             | <b>-13 164</b> | <b>-2 028</b>        | <b>65 882</b> |
| Outline of previous year's results               |               |                     |                           | -2 028         | 2 028                | 0             |
| Issue of warrants                                |               |                     |                           | 2 027          |                      | 2 027         |
| Issue costs                                      |               |                     | -1 968                    |                |                      | -1 968        |
| Rights issue                                     | 262           |                     | 33 188                    |                |                      | 33 450        |
| Ongoing share issue                              |               | 1 068               |                           |                |                      | 1 068         |
| The result of the period                         |               |                     |                           |                | -3 809               | -3 809        |
| <b>At the end of the period (31/12-2021)</b>     | <b>1 748</b>  | <b>1 068</b>        | <b>110 808</b>            | <b>-13 165</b> | <b>-3 809</b>        | <b>96 650</b> |

# ADDITIONAL DISCLOSURES

## NOTE 1

### ACCOUNTING AND VALUATION POLICIES

The Group and the Parent Company apply the Swedish Annual Accounts Act as well as the Swedish Accounting Standards Board BFNAR 2012:1 annual report and consolidated (K3) in the preparation of financial reports.

#### *Reporting currency*

The annual report is prepared in Swedish kronor.  
Amounts are stated in KSEK unless specified otherwise.

#### *Consolidated financial statements*

The consolidated accounts cover the parent company and those subsidiaries in which the parent company directly or indirectly holds more than 50 percent of the voting rights or otherwise has a controlling influence. The consolidated accounts have been prepared according to the purchase method, which entails that equity in the subsidiaries at the time of acquisition is eliminated in full. The Group's equity thus only includes the portion of equity of each subsidiary that has been added after the acquisition.

If the consolidated cost of acquisition of the subsidiaries' shares exceed the fair value of the net assets according to the acquisition analysis, the difference is recognized as goodwill on consolidation.

Intra-group balances and internal profits are eliminated in full.

The translation of foreign subsidiaries is carried out using the current method. This means that the balance sheets are translated at the exchange rates on the balance sheet date, and the income statements are translated at the average exchange rates during the period. The arising translation differences are recognized directly in equity.

#### *Cash flow statement*

The cash flow statement is drawn up using the indirect method, with adjustments made for the effects of non-cash transactions. In addition to cash and bank balances and group account balances, cash equivalents include short-term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

#### *Revenue recognition*

The Group's revenue mostly comprises received contributions and grants which are recognized as revenue for the period in which the work associated with the received contributions and grants is performed. When applicable, the revenue can be offset against the cost that the grant or contribution is intended to cover. If the contribution or grant is subject to terms that may lead to a repayment obligation, the recognition of revenue takes place only when it is possible to foresee with a sufficient degree of probability that the contribution or grant will not be recovered.

#### *Internally generated intangible fixed assets*

The capitalization model is used for recognizing development expenses, meaning that such expenses are recognized as intangible fixed assets when all of the factors below have been fulfilled:

- It is technically and financially possible to complete the asset
- There is intent and prerequisite to use or sell the asset
- It is likely that the asset will generate revenue or give rise to cost savings
- The expenses can be reliably calculated

The cost of an internally generated intangible asset comprises all directly attributable development expenditure that is required for the asset to be used in the manner intended by the management.

As of the balance sheet date, all internally generated intangible fixed assets are amortized in full.

*Tangible fixed assets*

Tangible fixed assets are recognized at cost less depreciation according to plan on the basis of the estimated useful life of each asset. The following depreciation periods are applied by the parent company as well as the group companies.

EQUIPMENT, TOOLS, FIXTURES AND FITTINGS: 5 years

*Receivables and liabilities in foreign currency*

Receivables and liabilities in foreign currency are translated at the exchange rate at the balance sheet date. The difference between cost and the value at the balance sheet date is recognized through the income statement. To the extent that receivables and liabilities in foreign currency are subject to hedging, they are translated using the forward rate.

*Impairment losses*

If an indication is found of fall in value of an asset, the asset's recoverable amount is determined. If the carrying amount exceeds the recoverable amount, the asset is written down to the lower amount. The recoverable amount is defined as the highest of the fair value and the value in use. The value in use is defined as the present value of the estimated future cash flows that the asset will generate.

Impairment losses are recognized through the income statement.

*Income taxes*

Reporting of income taxes include current tax and deferred tax. Taxes are reported in the income statement, unless the tax is attributable to an event or transaction that is reported directly in equity. In such events, related tax effects are also recognized in equity. Deferred tax is recognized according to the balance sheet method for all material temporary differences. Temporary differences arise when the book value differs from the tax value of an asset or a liability. Deferred tax liabilities are calculated on the basis of the tax rates that are decided or announced at the balance sheet date, currently 20,6 percent. Deferred tax assets are recognized to the extent that it is probable that taxable profits will be available against which the deductible temporary differences can be utilized.

The Group recognizes tax reliefs relating to R&D work in Denmark in accordance with the Danish tax rules.

*Financial instruments*

Financial assets and liabilities are recognized using the cost model. Long-term receivables and short-term liabilities are measured at amortized cost, which corresponds to the present value of the remaining payments discounted using the effective interest rate calculated at the time of acquisition. Short-term receivables are recognized at cost or net realizable value, whichever is lowest. Current liabilities, which are expected to be settled within 12 months, are measured at the nominal amount.

*Borrowings*

The Group has no borrowings as of 31 December 2021.

*Accounts payable*

Accounts payable are payment obligations related to goods or services acquired from suppliers in the course of the operating activities. Accounts payable are classified as short-term liabilities if they fall due for payment within one year.

*Warrant program for employees and Board members*

The extra general meeting on 5 November 2020 resolved to establish a warrant program for 3 new board members. The warrant program totalling 120,000 warrants carry the right to subscribe for newly issued shares in 2cureX AB in the period from 1 October 2023 up to and including 31 December 2023. Each subscription warrant entitles the holder to subscribe for 1 share, at a subscription price equal to 110 percent of the volume weighted average price at Nasdaq First North Growth Market during a period of ten trading days following the extra general meeting on 5 November 2020. Upon full exercise of the issued warrants, the share capital would increase by 12,000 SEK. The warrants will be subject to the usual conversion terms in connection with new share issues etc.

The Annual General Meeting on 27 May 2021 resolved to establish a Series 2021/24 warrant program for the Group's CEO. The warrants, totalling 700 000 warrants, carry the right to subscribe for newly issued shares in 2cureX AB in the period 1 April 2022 to 30 June 2022 (233 333 warrants), in the period 1 April 2023 to 30 June 2023 (233 333 warrants) and in the period 1 April 2024 to 30 June 2024 (233 334 warrants), respectively.

The Group's result for 2021 has been impacted by costs in the amount of 2 027 KSEK (399 KSEK) in the form of personnel costs.

## ACCOUNTING POLICIES OF THE PARENT COMPANY

*Participations in Group companies*

In the parent company, participations in Group companies are initially recognized at cost, which includes any transaction expenses that are directly attributable to the acquisition of the shares. Share issue proceeds and shareholder contributions are added to the acquisition value. If the fair value is lower than the carrying amount, the shares are written down to the fair value if it can be assumed that the fall in value is permanent.

*Equity*

The parent company's equity is divided into restricted equity, consisting of share capital, and unrestricted equity, consisting of premium reserve, retained earnings and net profit for the year.

## NOTE 2

**ESTIMATES AND ASSESSMENTS**

The preparation of financial reports requires the management to make judgements and estimates that affect the reported amounts of assets, liabilities, income and expenses. The actual outcome may differ from these estimates and assessments. Those estimates and assessments that may lead to a risk of having to materially adjust the carrying amounts of assets and liabilities are primarily the valuations of shares in Group companies.

It is examined every year whether there are any indications that the value of the assets is lower than the recognized value. If such an indication is found, the asset's recoverable amount is determined. This is the highest of the fair value of the asset less costs to sell and the value in use.

## DISCLOSURES ON INDIVIDUAL ITEMS

## NOTE 3

**OTHER OPERATING INCOME**

| Group                               | 2021         | 2020          |
|-------------------------------------|--------------|---------------|
| Received contributions              | 7 391        | 15 391        |
| <b>Total other operating income</b> | <b>7 391</b> | <b>15 391</b> |

## NOTE 4

**AVERAGE NUMBER OF EMPLOYEES, SALARIES AND OTHER REMUNERATIONS**

| Average number of employees     | 2021                |          |          | 2020                |          |          |
|---------------------------------|---------------------|----------|----------|---------------------|----------|----------|
|                                 | Number of employees | Woman    | Men      | Number of employees | Woman    | Men      |
| <i>Parent Company</i>           |                     |          |          |                     |          |          |
| Sweden                          | 0                   | 0        | 0        | 0                   | 0        | 0        |
| <i>Subsidiaries</i>             |                     |          |          |                     |          |          |
| Denmark                         | 9                   | 4        | 5        | 9                   | 4        | 5        |
| Germany                         | 5                   | 2        | 3        | 4                   | 2        | 2        |
| <b>Group in total</b>           | <b>14</b>           | <b>6</b> | <b>8</b> | <b>13</b>           | <b>6</b> | <b>7</b> |
| <i>Management</i>               |                     |          |          |                     |          |          |
| Board of Directors              | 6                   | 1        | 5        | 6                   | 1        | 5        |
| CEO and other senior executives | 2                   | 0        | 2        | 2                   | 0        | 2        |

|                                                  | 2021                       |                       | 2020                       |                       |
|--------------------------------------------------|----------------------------|-----------------------|----------------------------|-----------------------|
| Personnel costs                                  | Salaries and remunerations | Social security costs | Salaries and remunerations | Social security costs |
| Parent company<br>(of which pension costs)       | 763                        | 77<br>(0)             | 617                        | 42<br>(0)             |
| Subsidiaries<br>(of which pension costs)         | 14 488                     | 658<br>(0)            | 11 014                     | 687<br>(0)            |
| <b>Group, total<br/>(of which pension costs)</b> | <b>15 251</b>              | <b>735<br/>(0)</b>    | <b>11 631</b>              | <b>729<br/>(0)</b>    |

Specification of salaries and other remuneration for board members and the CEO for 2021

|                                            | Salary | Benefits | Pension | Total        |
|--------------------------------------------|--------|----------|---------|--------------|
| Povl-André Bendz, Chairman of the Board    | 300    | 0        | 0       | <b>300</b>   |
| Jörgen Drejer, Member of the board         | 150    | 0        | 0       | <b>150</b>   |
| Camilla Huse Bondsson, Member of the board | 150    | 0        | 0       | <b>150</b>   |
| Nils Brünner, Member of the board          | 150    | 0        | 0       | <b>150</b>   |
| Michael Lutz, Member of the board          | 150    | 0        | 0       | <b>150</b>   |
| Ole Thastrup, Member of the board          | 150    | 0        | 0       | <b>150</b>   |
| Fernando Andreu, CEO                       | 2 674  | 0        | 0       | <b>2 674</b> |

Specification of salaries and other remuneration for board members and the CEO for 2020

|                                            | Salary | Benefits | Pension | Total        |
|--------------------------------------------|--------|----------|---------|--------------|
| Povl-André Bendz, Chairman of the Board    | 200    | 0        | 0       | <b>200</b>   |
| Jörgen Drejer, Member of the board         | 100    | 0        | 0       | <b>100</b>   |
| Camilla Huse Bondsson, Member of the board | 100    | 0        | 0       | <b>100</b>   |
| Nils Brünner, Member of the board          | 100    | 0        | 0       | <b>100</b>   |
| Michael Lutz, Member of the board          | 100    | 0        | 0       | <b>100</b>   |
| Ole Thastrup, CEO                          | 1 637  | 0        | 0       | <b>1 637</b> |

The CEO of the parent company is remunerated through subsidiaries.

The following individuals within the Group have been allotted employee warrants free of charge. The warrant program impacts the Group's result for 2021 in the form of personnel costs in the amount of 2 026 KSEK (399 KSEK), including associated social security contributions.

|                               |                                         |                  |
|-------------------------------|-----------------------------------------|------------------|
| <b>Povl-André Bendz</b>       | <i>Chairman of the board, 2cureX AB</i> | 80 000 warrants  |
| <b>Jörgen Drejer</b>          | <i>Member of the board, 2cureX AB</i>   | 40 000 warrants  |
| <b>Michael Lutz</b>           | <i>Member of the board, 2cureX AB</i>   | 40 000 warrants  |
| <b>Camilla Huse Bondesson</b> | <i>Member of the board, 2cureX AB</i>   | 40 000 warrants  |
| <b>Nils Brünner</b>           | <i>Member of the board, 2cureX AB</i>   | 40 000 warrants  |
| <b>Fernando Andreu</b>        | <i>CEO, 2cureX A/S</i>                  | 700 000 warrants |

#### NOTE 5

##### PROFIT FROM PARTICIPATIONS IN GROUP COMPANIES

|                                                  | 2021          | 2020        |
|--------------------------------------------------|---------------|-------------|
| Parent Company                                   |               |             |
| Impairment loss on holdings associated companies | -2 027        | -399        |
| <b>Total</b>                                     | <b>-2 027</b> | <b>-399</b> |

#### NOTE 6

##### OTHER INTEREST INCOME AND SIMILAR ITEMS

|                                           | Group      |          | Parent Company |            |
|-------------------------------------------|------------|----------|----------------|------------|
|                                           | 2021       | 2020     | 2021           | 2020       |
| Interest income from associated companies | 0          | 0        | 957            | 942        |
| Currency exchange differences             | 426        | 0        | 0              | 0          |
| <b>Total</b>                              | <b>426</b> | <b>0</b> | <b>957</b>     | <b>942</b> |



## NOTE 7

## INTEREST COSTS AND SIMILAR ITEMS

|                               | Group       |               | Parent Company |            |
|-------------------------------|-------------|---------------|----------------|------------|
|                               | 2021        | 2020          | 2021           | 2020       |
| Interest expenses             | -104        | -240          | -2             | -78        |
| Currency exchange differences | 0           | -933          | 0              | 0          |
| <b>Total</b>                  | <b>-104</b> | <b>-1 173</b> | <b>-2</b>      | <b>-78</b> |

## NOTE 8

## TAX ON PROFIT FOR THE YEAR

|                                                            | Group        |              | Parent Company |          |
|------------------------------------------------------------|--------------|--------------|----------------|----------|
|                                                            | 2021         | 2020         | 2021           | 2020     |
| Current tax                                                | 3 542        | 1 271        | 0              | 0        |
| Deferred tax liabilities                                   | 0            | 0            | 0              | 0        |
| <i>Theoretical tax</i>                                     |              |              |                |          |
| Reported profit before tax                                 | -22 479      | -8 591       | -3 809         | -2 028   |
| Tax according to the applicable tax rate,<br>20,6% (21,4%) | 4 631        | 1 838        | 784            | 434      |
| <i>Reconciliation of recognized tax</i>                    |              |              |                |          |
| Non-deductible costs                                       | -14          | -2           | -13            | -85      |
| Effect of foreign tax                                      | -978         | -530         | 0              | 0        |
| Unvalued loss carryforwards                                | -97          | -35          | -771           | -349     |
| <b>Total</b>                                               | <b>3 542</b> | <b>1 271</b> | <b>0</b>       | <b>0</b> |

Tax loss carryforwards amount to 8 244 KSEK (6 467 KSEK) for the parent company. Tax loss carryforwards for the Group amount to 23 968 KSEK (19 041 KSEK). Deferred tax assets have not been taken into account. Tax loss carryforwards are not limited in time.

## NOTE 9

## CAPITALIZED DEVELOPMENT EXPENDITURE

| Group                                            | 31/12-2021    | 31/12-2020    |
|--------------------------------------------------|---------------|---------------|
| Cost, opening balance                            | 4 048         | 4 889         |
| Disposal/scraping                                | 0             | -703          |
| Translation differences for the year             | 78            | -138          |
| <i>Accumulated cost, closing balance</i>         | <i>4 126</i>  | <i>4 048</i>  |
| Amortization, opening balance                    | -4 048        | -4 889        |
| Disposal/scraping                                | 0             | 703           |
| Translation differences for the year             | -78           | 138           |
| <i>Accumulated amortization, closing balance</i> | <i>-4 126</i> | <i>-4 048</i> |
| <b>Reported value</b>                            | <b>0</b>      | <b>0</b>      |

## NOTE 10

## EQUIPMENT, TOOLS, FIXTURES AND FITTINGS

| Group                                            | 31/12-2021    | 31/12-2020    |
|--------------------------------------------------|---------------|---------------|
| Cost, opening balance                            | 3 066         | 2 729         |
| Acquisitions for the year                        | 32            | 403           |
| Divestments for the year                         | 0             | 0             |
| Translation differences for the year             | -86           | -66           |
| <i>Accumulated cost, closing balance</i>         | <i>3 012</i>  | <i>3 066</i>  |
| Depreciation, opening balance                    | -2 070        | -1 714        |
| Depreciation for the year                        | -353          | -386          |
| Divestments for the year                         | 0             | 0             |
| Translation differences for the year             | 102           | 30            |
| <i>Accumulated depreciation, closing balance</i> | <i>-2 321</i> | <i>-2 070</i> |
| <b>Reported value</b>                            | <b>691</b>    | <b>996</b>    |

## NOTE 11

## PARTICIPATIONS IN GROUP COMPANIES

| Parent Company                                 | 31/12-2021     | 31/12-2020     |
|------------------------------------------------|----------------|----------------|
| Cost, opening balance                          | 15 580         | 15 181         |
| Shareholder contributions                      | 2 027          | 399            |
| <i>Accumulated cost, closing balance</i>       | <i>17 607</i>  | <i>15 580</i>  |
| Impairment, opening balance                    | -10 580        | -10 181        |
| Impairment for the year                        | -2 027         | -399           |
| <i>Accumulated impairment, closing balance</i> | <i>-12 607</i> | <i>-10 580</i> |
| <b>Reported value</b>                          | <b>5 000</b>   | <b>5 000</b>   |

| Specifications of subsidiaries | Reg. no.    | Registered office | Number of shares | Share of capital and votes | Reported value |
|--------------------------------|-------------|-------------------|------------------|----------------------------|----------------|
| 2cureX A/S                     | 29 41 88 88 | Copenhagen        | 500 000          | 100%                       | 5 000          |
| 2cureX GmbH                    | HRB 137736  | Hamburg           | 25 000           | (100%)                     | –              |

## NOTE 12

## EQUITY

There are 17 475 716 shares, each with a quota value of 0.10 SEK.

## NOTE 13

## RECEIVABLES FROM GROUP COMPANIES

| Parent Company                    | 31/12-2021    | 31/12-2020    |
|-----------------------------------|---------------|---------------|
| Cost, opening balance             | 23 318        | 22 376        |
| Changes for the year              | 957           | 942           |
| Accumulated cost, closing balance | 24 275        | 23 318        |
| <b>Reported value</b>             | <b>24 275</b> | <b>23 318</b> |
| Distribution of receivables:      |               |               |
| 2cureX A/S                        | 24 275        | 23 318        |
| 2cureX GmbH                       | 0             | 0             |

## NOTE 14

## ACCRUALS AND DEFERRED INCOME

|                         | Group        |              | Parent Company |            |
|-------------------------|--------------|--------------|----------------|------------|
|                         | 2021         | 2020         | 2021           | 2020       |
| Personnel-related costs | 1 134        | 909          | 0              | 0          |
| Other accrued expenses  | 310          | 1 254        | 310            | 536        |
| <b>Total</b>            | <b>1 444</b> | <b>2 163</b> | <b>310</b>     | <b>536</b> |

## NOTE 15

## NON-CASH ITEMS

|                                         | Group        |            | Parent Company |          |
|-----------------------------------------|--------------|------------|----------------|----------|
|                                         | 2021         | 2020       | 2021           | 2020     |
| Depreciation                            | 353          | 386        | 0              | 0        |
| Issue of warrants                       | 2 027        | 399        | 0              | 0        |
| Realized results, tangible fixed assets | 0            | 0          | 0              | 0        |
| Translation differences                 | -452         | -101       | 0              | 0        |
| <b>Total</b>                            | <b>1 928</b> | <b>684</b> | <b>0</b>       | <b>0</b> |

## NOTE 16

## PREPAYMENTS AND ACCRUED INCOME

|                        | Group      |              | Parent Company |            |
|------------------------|------------|--------------|----------------|------------|
|                        | 2021       | 2020         | 2021           | 2020       |
| EU contribution        | 0          | 932          | 0              | 0          |
| Prepaid board fees     | 287        | 0            | 287            | 0          |
| Other prepaid expenses | 260        | 205          | 183            | 159        |
| <b>Total</b>           | <b>547</b> | <b>1 137</b> | <b>470</b>     | <b>159</b> |

## NOTE 17

## CASH AND CASH EQUIVALENTS

|               | Group         |               | Parent Company |               |
|---------------|---------------|---------------|----------------|---------------|
|               | 2021          | 2020          | 2021           | 2020          |
| Bank balances | 72 942        | 58 577        | 67 176         | 37 961        |
| <b>Total</b>  | <b>72 942</b> | <b>58 577</b> | <b>67 176</b>  | <b>37 961</b> |

## NOTE 18

## APPROPRIATION OF PROFIT OR LOSS

Proposed appropriations of the company's result (SEK)

The following funds are available to the Annual General Meeting:

|                                                             |                   |
|-------------------------------------------------------------|-------------------|
| Premium reserve                                             | 111 864 370       |
| Retained earnings                                           | -13 165 683       |
| Net profit or loss for the year                             | -3 809 245        |
|                                                             | <b>94 889 442</b> |
| The Board of Directors proposes the following distribution: |                   |
| To be carried forward                                       | 94 889 442        |
|                                                             | <b>94 889 442</b> |

## NOTE 19

## CONTINGENT LIABILITIES

|                   | 31/12-2021 | 31/12-2020 |
|-------------------|------------|------------|
| Rental commitment | 139        | 133        |
| <b>Total</b>      | <b>139</b> | <b>133</b> |

## NOTE 20

## RELATED PARTY TRANSACTIONS

The members of the board and other key individuals within the Group have been allotted employee options free of charge. No other related party transactions have occurred except for the remuneration on market conditions of the members of the board and other key individuals within the Group (see Note 4 for more information).

## NOTE 21

**SIGNIFICANT EVENTS AFTER THE REPORTING PERIOD**

The Group and the parent company are aware of the situation from the post COVID-19 outbreak and the unfortunate situation regarding Ukraine, and the risk that this may impact the Group and the parent company adversely. The management of the company have assessed that this impact will not have a significant effect on the financial position of the Group or the parent company. The management is continuously monitoring the situation and assess that measures such as conversions and cost savings quickly can be imposed to counteract deteriorating results.

In the time after the reporting period, following significant events have occurred:

- New Institutional shareholder
- New Distributor for IndiTreat® in Czech Republic and Slovakia through Promedica, and in Poland through Perlan Technologies
- 2cureX launches IndiTreat® mCRC Explore and completes portfolio rollout plan for 2022
- Chairman of the 2cureX Board exercises all warrants within the framework of the 2018 incentive program
- Manuel Fernández joins 2cureX as Director of Quality Assurance and Regulatory Affairs.

## NOTE 22

**PARENT COMPANY**

2cureX AB (publ), corporate registration number 559128-0077, is the parent company of a group and prepares consolidated accounts.

2cureX AB is seated in Malmö, Skåne county, with the address:  
c/o Mazars SET, Revisionsbyrå AB, Box 159, 261 22 Landskrona, Sweden.

# ANNUAL REPORT 2021

Malmö, May 3, 2022

## BOARD OF DIRECTORS

---

Povl-André Bendz  
*Chairman of the Board*

---

Jørgen Drejer  
*Member of the board*

---

Camilla Huse Bondesson  
*Member of the board*

---

Michael Lutz  
*Member of the board*

---

Nils Brünner  
*Member of the board*

---

Fernando Andreu  
*CEO*

Our audit report was submitted on May 3, 2022  
Öhrlings PricewaterhouseCoopers AB

---

Ole Thastrup  
*Member of the Board*

---

Cecilia Andrén Dorselius  
*Chartered Accountant*



# AUDITOR'S REPORT

UNOFFICIAL TRANSLATION

**To the general meeting of the shareholders of 2cureX AB (publ), corporate identity number 559128-0077**

## REPORT ON THE ANNUAL ACCOUNTS AND CONSOLIDATED ACCOUNTS

### *Opinions*

We have audited the annual accounts and consolidated accounts of 2cureX AB (publ) for the year 2021. The annual accounts and consolidated accounts of the company are included on pages 23-43 in this document.

In our opinion, the annual accounts and consolidated accounts have been prepared in accordance with the Annual Accounts Act and present fairly, in all material respects, the financial position of parent company and the group as of 31 December 2021 and its financial performance and cash flow for the year then ended in accordance with the Annual Accounts Act. The statutory administration report is consistent with the other parts of the annual accounts and consolidated accounts.

We therefore recommend that the general meeting of shareholders adopts the income statement and balance sheet for the parent company and the group.

### *Basis for Opinions*

We conducted our audit in accordance with International Standards on Auditing (ISA) and generally accepted

auditing standards in Sweden. Our responsibilities under those standards are further described in the Auditor's Responsibilities section. We are independent of the parent company and the group in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinions.

### *Other Information than the annual accounts and consolidated accounts*

This document also contains other information than the annual accounts and consolidated accounts and is found on pages 1-22. The Board of Directors and the Managing Director are responsible for this other information.

Our opinion on the annual accounts and consolidated accounts does not cover this other information and we do not express any form of assurance conclusion regarding this other information.

In connection with our audit of the annual accounts and consolidated accounts, our responsibility is to read the information identified above and consider whether the information is materially inconsistent with the annual accounts and consolidated accounts. In this procedure we also take into account our knowledge otherwise obtained in the audit and assess whether the information otherwise appears to be materially misstated.

If we, based on the work performed concerning this information, conclude that there is a material misstatement of this other information, we are required to report that

fact. We have nothing to report in this regard.

### *Responsibilities of the Board of Directors and the Managing Director*

The Board of Directors and the Managing Director are responsible for the preparation of the annual accounts and consolidated accounts and that they give a fair presentation in accordance with the Annual Accounts Act. The Board of Directors and the Managing Director are also responsible for such internal control as they determine is necessary to enable the preparation of annual accounts and consolidated accounts that are free from material misstatement, whether due to fraud or error.

In preparing the annual accounts and consolidated accounts, The Board of Directors and the Managing Director are responsible for the assessment of the company's and the group's ability to continue as a going concern. They disclose, as applicable, matters related to going concern and using the going concern basis of accounting. The going concern basis of accounting is however not applied if the Board of Directors and the Managing Director intend to liquidate the company, to cease operations, or has no realistic alternative but to do so.

### *Auditor's responsibility*

Our objectives are to obtain reasonable assurance about whether the annual accounts and consolidated accounts as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinions. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and generally accepted auditing standards in Sweden will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably

be expected to influence the economic decisions of users taken on the basis of these annual accounts and consolidated accounts.

A further description of our responsibility for the audit of the annual accounts and consolidated accounts is available on Revisorsinspektionen's website:

[www.revisorsinspektionen.se/revisornsansvar](http://www.revisorsinspektionen.se/revisornsansvar).

This description is part of the auditor's report.

## REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENTS

### *Opinions*

In addition to our audit of the annual accounts and consolidated accounts, we have also audited the administration of the Board of Directors and the Managing Director of 2cureX AB (publ) for the year 2021 and the proposed appropriations of the company's profit or loss.

We recommend to the general meeting of shareholders that the profit be appropriated in accordance with the proposal in the statutory administration report and that the members of the Board of Directors and the Managing Director be discharged from liability for the financial year.

### *Basis for Opinions*

We conducted the audit in accordance with generally accepted auditing standards in Sweden. Our responsibilities under those standards are further described in the Auditor's Responsibilities section. We are independent of the parent company and the group in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinions.

### *Responsibilities of the Board of Directors and the Managing Director*

The Board of Directors is responsible for the proposal for appropriations of the company's profit or loss. At the proposal of a dividend, this includes an assessment of whether the dividend is justifiable considering the requirements which the company's and the group's type of operations, size and risks place on the size of the parent company's and the group's equity, consolidation requirements, liquidity and position in general.

The Board of Directors is responsible for the company's organization and the administration of the company's affairs. This includes among other things continuous assessment of the company's and the group's financial situation and ensuring that the company's organization is designed so that the accounting, management of assets and the company's financial affairs otherwise are controlled in a reassuring manner. The Managing Director shall manage the ongoing administration according to the Board of Directors' guidelines and instructions and among other matters take measures that are necessary to fulfill the company's accounting in accordance with law and handle the management of assets in a reassuring manner.

### *Auditor's responsibility*

Our objective concerning the audit of the administration, and thereby our opinion about discharge from liability, is to obtain audit evidence to assess with a reasonable degree of assurance whether any member of the Board of

Directors or the Managing Director in any material respect:

- has undertaken any action or been guilty of any omission which can give rise to liability to the company, or
- in any other way has acted in contravention of the Companies Act, the Annual Accounts Act or the Articles of Association.

Our objective concerning the audit of the proposed appropriations of the company's profit or loss, and thereby our opinion about this, is to assess with reasonable degree of assurance whether the proposal is in accordance with the Companies Act.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with generally accepted auditing standards in Sweden will always detect actions or omissions that can give rise to liability to the company, or that the proposed appropriations of the company's profit or loss are not in accordance with the Companies Act.

A further description of our responsibility for the audit of the administration is available on Revisorsinspektionen's website: [www.revisorsinspektionen.se/revisornsansvar](http://www.revisorsinspektionen.se/revisornsansvar).

This description is part of the auditor's report.

Malmö May 3, 2022

Öhrlings PricewaterhouseCoopers AB

**Cecilia Andrén Dorselius**

*Authorized Public Accountant*

THE POWER OF PRECISION.  
FOR EVERY ONCOLOGIST.  
TODAY.



**2CUREX AB** (publ)

Fruebjergvej 3 / DK-2100 Copenhagen / Denmark  
Phone: +45 2211 5399 / E-mail: [info@2curex.com](mailto:info@2curex.com)